12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lambrolizumab regulatory update

Merck said FDA granted breakthrough therapy designation for its lambrolizumab to treat advanced melanoma. The humanized mAb against programmed cell death...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >